Contact:
Jeanne-Marie Phillips
HealthFlash Marketing
203-977-3333
Sharon Grutman
The American Society of Breast Surgeons
877-992-5470
Radiofrequency Ablation Prevents Local Cancer Recurrence as
Effectively as Radiation Therapy
Using Heat to Extend the Tumor-Free Zone an Effective Complement to Lumpectomy
Abstract: Long-Term Results of Excision Followed by Radiofrequency Ablation (eRFA) as the Sole Local
Therapy for Breast Cancer
May 4, 2012, Phoenix--Radiofrequency ablation of the lumpectomy site during breast cancer surgery
can provide an effective alternative to post-operative external radiation therapy (XRT) and reduce
repeat surgeries to achieve clear tumor margins, according to one of the first published long-term
studies to examine this new treatment protocol. Researchers reported this week at the American
Society of Breast Surgeons (ASBrS) Annual Meeting that utilizing radiofrequency-generated heat to
create an added disease-free zone around the tumor cavity is at least as effective in preventing local
tumor recurrence as XRT following surgery. In many cases, ablation also extended the disease-free zone
sufficiently to eliminate the need for repeat surgery to correct inadequate disease-free tumor margins
identified in post-operative pathology examination.
“Radiation has a range of difficult side effects, including shrinkage of breast tissue, loss of sensation and
damage to nearby healthy tissue,” comments lead study author V. Suzanne Klimberg, MD, FACS, Muriel
Balsam Chair in Surgical Oncology and Professor of Surgery and Pathology at the University of Arkansas
for Medical Sciences, Director of the Breast Cancer Program at the Winthrop P. Rockefeller Institute of
the University of Arkansas for Medical Sciences, and President-Elect of the ASBrS. “Additionally, for
patients in rural areas in the US and around the world, XRT—the standard of care following lumpectomy
surgery—simply isn’t an option if a therapy center is not located nearby. Today, these patients have no
choice but mastectomy.”
5950 Symphony Woods Road, Suite 212, Columbia, MD 21044 USA ● Phone: 410-992-5470, 877-992-5470 (toll free) ● Fax: 410-992-5472
www.breastsurgeons.org ● contact@breastsurgeons.org
2
In the study, 60 patients with invasive cancer underwent tumor excision (lumpectomy surgery) followed
by radiofrequency ablation (eRFA) at 100 degrees C for 15 minutes with a real-time radiofrequency
probe to extend the radius of the lumpectomy cavity by 1 cm. None of the patients received adjunctive
XRT.
Patients in the study were followed with a mammogram and physical exam every six months for the first
two years and yearly thereafter. During the nine year study, patients have been followed for an average
of 44 months post-op, (ranging from 12 to 84 months). The study reports on a subset of 60 patients
treated for invasive cancer with a lumpectomy and intraoperative RFA as an alternative to XRT. None of
these patients received chemotherapy.
Pathology reports following surgery found that tumor margins were cancer-free in 44 patients, focally
positive in 3, close in 11 and grossly positive in 2. It had been previously determined that because of the
ablation-extended margins, only patients with grossly positive margins on post-operative pathology or
residual calcifications on postoperative mammography would require additional excision of the tumor
bed. In the study, 14 out of 16 patients who would have returned to the operating room (OR) with
similar margin findings and XRT were spared additional surgery.
Only one patient (1.7%) recurred with a cancer nearby the original tumor site. One patient developed a
cancer at a distant location.
“The recurrence rate for lumpectomy with follow up radiation is 1 % per year for the first five years and
then about ½ % annually thereafter,” comments Misti H. Wilson, MD, Breast Fellow and Instructor in the
Department of Surgery at the University of Arkansas for Medical Science, another study author.
“Patients in this study did extremely well. Without the side effects of radiation, radiofrequency ablation
is an extremely appealing choice. The ablated tissue remains in the breast, so less breast mass is lost
than with radiation, and post-treatment tissue shrinkage is not a problem. The cosmetic results are
excellent. Often, you can barely tell a patient has had surgery.”
Dr. Klimberg also notes that the eRFA has a range of practical advantages compared to radiation
therapy. eRFA is delivered by the breast surgeon and does not require extensive special training. Unlike
radiation, it can be delivered in any OR with no equipment other than an RFA probe and does not
require follow-up treatment.
5950 Symphony Woods Road, Suite 212, Columbia, MD 21044 ● Phone: 410-992-5470, 877-992-5470 (toll free) ● Fax: 410-992-5472
www.breastsurgeons.org ● contact@breastsurgeons.org
3
RFA has been successfully used for many years to treat a range of other types of cancer by destroying
the entire tumor. But its application in breast cancer has been difficult due to the characteristics of
breast tissue. Only recently have surgeons begun exploring it as an alternative to XRT to extend the
margins of the tumor bed.
Based on the results of this study, eRFA is now being examined in a multicenter ABLATE (Radiofrequency
Ablation after Breast Lumpectomy Added to Extend Intraoperative Margins) trial. To date, the trial
includes five centers (Columbia University, University of Kansas, Comprehensive Breast Care of San
Diego, University of Arizona and Rockefeller Cancer Institute in Little Rock) and is actively recruiting and
training additional sites (http://surgery.uams.edu.ablate).
5950 Symphony Woods Road, Suite 212, Columbia, MD 21044 ● Phone: 410-992-5470, 877-992-5470 (toll free) ● Fax: 410-992-5472
www.breastsurgeons.org ● contact@breastsurgeons.org
4
0136 Long-Term Results of Excision Followed by Radiofrequency Ablation (eRFA) as the Sole
Local Therapy for Breast Cancer
Misti Wilson, Sohelia Korourian, Christiano Boneti, Laura Adkins, Brian Badgewell, Jeanette Lee, V
Suzanne Klimberg
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Objectives: Clinical trials have yet to find a size or grade of invasive cancer that can be treated with
lumpectomy alone due to the higher local recurrence (LR) rate without radiation (XRT). Even with
advanced tumor localization techniques and our best efforts, a large percentage of patients require reexcision for positive margins, which can be costly, time-consuming, and stressful for the patients.
Adjuvant radiation also adds significant cost and morbidity to the breast cancer patient treatment regimen.
Excision followed by radiofrequency ablation (eRFA) is an intraoperative method that utilizes heat to
create an additional tumor-free zone around the lumpectomy cavity approximating the zone treated by
brachytherapy. We hypothesized that eRFA after lumpectomy for invasive breast cancer could reduce the
need for re-excision by extending the margin of tumor-free zone and maintain local control without XRT.
Method: We conducted an IRB-approved Phase II trial of patients with invasive breast cancer receiving
lumpectomy followed by immediate intraoperative eRFA. Patients with tumors less than or equal to 3 cm
with clinically negative nodes were included. A standard lumpectomy was performed then the RFA probe
was deployed 1 cm circumferentially into the walls of the lumpectomy cavity. RFA maintained at 100
degrees C for 15 min has been shown in preclinical and clinical data to extend the lumpectomy margin by
1 cm. Validated Doppler sonography was used to determine final ablation size. Cosmesis was good.
Standard H&E of lumpectomy margins was performed. None of these patients received XRT. Only
patients with grossly positive lumpectomy margins was performed. None of these patients received XRT.
Only patients with grossly positive margins or residual calcifications on postoperative mammography were
re-resected. Patients were followed every 6 months for the first 2 years and yearly thereafter with
mammogram and physical exam.
Results: Sixty patients (mean age of 68.7 ± 11.4 years) with invasive cancer who had an average tumor
size of 1.1 cm ± 0.61 (range, 0.2 to 2.5 cm) underwent excision followed by radiofrequency ablation. Fiftysix patients had invasive ductal carcinoma and 4 had invasive lobular carcinoma. Thirty-three patients
had grade I disease, 21 had grade II, and 6 had grade III. Margins were negative in 44, focally positive in
3, close in 11, and grossly positive in 2. Fourteen of 16 (87%) patients with close or positive margins were
spared re-excision. Thirty-three patients were treated with hormonal therapy. Overall there were 5 deaths
total, none of which were related to their primary disease. After follow-up for 44 (12-84) months, only 1
patient (1.7%) developed an in site recurrence. There was 1 recurrence at another site. Average
cosmesis rating was good to excellent.
Conclusions: Long-term follow-up suggests that eRFA could reduce the need for re-excision, as well as
reduce local recurrence for invasive breast cancer treated without XRT. For selected breast cancer
patients undergoing breast conservation therapy, eRFA is an attractive alternative to breast irradiation.
This concept has recently initiated a multicenter register trial called ABLATE (Adjunctive Breast
Lumpectomy With RF Ablation Treatment to Reduce Re-Excision & Recurrence) in patients undergoing
conservative breast surgery.
5950 Symphony Woods Road, Suite 212, Columbia, MD 21044 ● Phone: 410-992-5470, 877-992-5470 (toll free) ● Fax: 410-992-5472
www.breastsurgeons.org ● contact@breastsurgeons.org